EC Number   |
Application |
Reference |
|---|
   1.8.1.B1 | analysis |
development of a cost sensitive classification model to evaluate the biological activity of inhibitors. Random forest analysis revealed 10 highly enriched scaffolds in the actives dataset. Models are evaluated using docking approaches |
743839 |
| 1.8.1.B1 | drug development |
identification of inhibitory compounds facilitates further development of anti-schistosomiasis drugs with novel mechanism of action |
763812 |
| 1.8.1.B1 | medicine |
enzyme can be used as a diagnostic target antigen for Schistosama mansoni infection in serum and urine. Sandwich ELISA detects the protein with high diagnostic efficiency in individuals with high or low worm burden |
743070 |
| 1.8.1.B1 | medicine |
identification of oxadiazole 2-oxides (TGR inhibitors) as new lead compounds for schistosomiasis chemotherapy |
689132 |
| 1.8.1.B1 | medicine |
quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade, several of which are highly potent and should serve both as mechanistic tools for probing the redox balance in Schistosome mansoni, and starting points for developing medicinal leads for treatments for schistosomiasis |
689707 |
| 1.8.1.B1 | medicine |
TGR is a key target for antischistosomal drug development |
689706 |
| 1.8.1.B1 | medicine |
the enzyme is a drug target for schistosomiasis |
724324 |
| 1.8.1.B1 | medicine |
the enzyme is a drug target in schistosomiasis |
724422 |
| 1.8.1.B1 | medicine |
the enzyme is a potential target for development of novel agents against schistosomes |
726293 |
| 1.8.1.B1 | medicine |
the enzyme is a promising target for anti Fasciola treatments |
724926 |
